Cargando…
Essential thrombocythemia
Essential thrombocythemia (ET) is an acquired myeloproliferative disorder (MPD) characterized by a sustained elevation of platelet number with a tendency for thrombosis and hemorrhage. The prevalence in the general population is approximately 30/100,000. The median age at diagnosis is 65 to 70 years...
Autor principal: | Brière, Jean B |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2007
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1781427/ https://www.ncbi.nlm.nih.gov/pubmed/17210076 http://dx.doi.org/10.1186/1750-1172-2-3 |
Ejemplares similares
-
Emerging treatments for essential thrombocythemia
por: Okoli, Steven, et al.
Publicado: (2011) -
Essential Thrombocythemia in Children and Adolescents
por: Putti, Maria Caterina, et al.
Publicado: (2021) -
Ruxolitinib for the Treatment of Essential Thrombocythemia
por: Gunawan, Arief, et al.
Publicado: (2018) -
Ruxolitinib for essential thrombocythemia?
por: Bose, Prithviraj, et al.
Publicado: (2017) -
Recent advances in understanding myelofibrosis and essential thrombocythemia
por: Vainchenker, William, et al.
Publicado: (2016)